Novo Nordisk slides to $40.99, down 13.56%, on Feb 23, 2026 after CagriSema miss

On February 23, 2026, Novo Nordisk shares fell in premarket trading after the company said CagriSema did not demonstrate non-inferiority to Eli Lilly's tirzepatide in the REDEFINE 4 study. At 5:27 AM EST, NVO traded at $40.99, down $6.43 or 13.56% from the prior close.